Dynavax Technologies (NASDAQ:DVAX) Cut to Hold at StockNews.com

StockNews.com lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a research note published on Wednesday.

DVAX has been the subject of a number of other reports. The Goldman Sachs Group began coverage on Dynavax Technologies in a research report on Thursday, February 1st. They issued a neutral rating and a $20.00 price objective for the company. William Blair restated an outperform rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $25.00.

Dynavax Technologies Trading Up 4.1 %

Shares of NASDAQ:DVAX opened at $11.80 on Wednesday. Dynavax Technologies has a 52-week low of $10.06 and a 52-week high of $15.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. The company has a market capitalization of $1.54 billion, a P/E ratio of -196.63 and a beta of 1.26. The company has a 50-day simple moving average of $12.33 and a 200 day simple moving average of $13.30.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.62% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE increased its position in Dynavax Technologies by 811.6% during the first quarter. Bank of America Corp DE now owns 4,340,287 shares of the biopharmaceutical company’s stock worth $42,578,000 after acquiring an additional 3,864,170 shares during the period. State Street Corp grew its position in Dynavax Technologies by 36.1% during the first quarter. State Street Corp now owns 8,498,732 shares of the biopharmaceutical company’s stock worth $92,126,000 after buying an additional 2,253,376 shares in the last quarter. Woodline Partners LP raised its holdings in Dynavax Technologies by 2,609.6% in the 2nd quarter. Woodline Partners LP now owns 1,782,398 shares of the biopharmaceutical company’s stock valued at $23,029,000 after acquiring an additional 1,716,617 shares in the last quarter. Eventide Asset Management LLC grew its holdings in shares of Dynavax Technologies by 103.0% during the 4th quarter. Eventide Asset Management LLC now owns 2,893,435 shares of the biopharmaceutical company’s stock worth $40,450,000 after purchasing an additional 1,468,435 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Dynavax Technologies by 63.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,931,727 shares of the biopharmaceutical company’s stock worth $28,759,000 after purchasing an additional 1,140,347 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.